Oncolytics Biotech Inc (ONCY) stock
ONCYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 10-Q on Nov 13, 2026Score 0/30
$0.44+0.06 (+15.11%)
Close on Nov 18, 2026Market cap $56.14MP/E –Yield –
Oncolytics Biotech r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2024 it was C$21.65M, up 22.2% from the year before. The highest annual figure on record is C$21.65M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | C$21.65M | +22.2% |
| FY2023 | Dec 31, 2023 | C$17.71M | +14.8% |
| FY2022 | Dec 31, 2022 | C$15.43M | +19.4% |
| FY2021 | Dec 31, 2021 | C$12.92M | -0.2% |
| FY2020 | Dec 31, 2020 | C$12.95M | +19.7% |
| FY2019 | Dec 31, 2019 | C$10.82M | +7.9% |
| FY2018 | Dec 31, 2018 | C$10.03M | +6.8% |
| FY2017 | Dec 31, 2017 | C$9.39M | -3.9% |
| FY2016 | Dec 31, 2016 | C$9.77M | +13.6% |
| FY2015 | Dec 31, 2015 | C$8.60M | – |
See a number that looks wrong?